Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High- versus low-dose ambrisentan in paediatric pulmonary arterial hypertension
2010-019547-19Phase 2Terminated
- Sponsor
- GSK
- Start
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ambrisentan in pulmonary arterial hypertension (PAH) (2 arms), sponsored by GSK. Primary endpoint: Safety and tolerability of ambrisentan. Started Jun 2010; status: terminated.
02
Drugs
ambrisentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2010-019547-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019547-19.